Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think it’s finally time to partner for Alzheimer’s and end all manipulation games.
Anavex really risks being aggressively taken over the longer they go it alone.
01DEC
ChrisMis day
I can imagine what a short is thinking right now…..
Where’s Bruce buffer when you need him!!
Suspicions on BIIB claims
The much trumpeted "27% slowing" is a relative value - the absolute difference on this test was 2.5%. In this image, I have re-scaled the result from the NEJM paper to include the absolute difference. [Values approximated using a graph extractor.]
Matthew Schrag
Maybe in his previous life.
Missling being from Missouri.
Oh snap. Someone just borrowed my shares on the ROBIN.
That’s why you partner!!
At least for the grand daddy of em all if the trial turns out to be beneficial for patients
Sounds like Remi more than Missling.
On a great note, it’s Mcfarlane that’ll be speaking so we SHOULDNT go down this time…..right?
Hope that brought a smile on this anxious day.
Good luck Missling et al.
If endpoints are met, a NEW MOA for CNS diseases will finally be front and center.
With it…..
FOMO
Yup. In hindsight, one could have doubled the amount of shares in just a measly month.
THAT would have been an awesome flip
Agree with the last sentence.
Crooks
One thing about Alzheimer’s, over time, you can’t “imagine” you are getting better.
Literally, you can’t “deal” yourself that hand.
Good luck bright and early Thursday morning.
Yup. Nothing fundamentally has changed besides trying to sow doubt before data read out.
No Missling didn’t insinuate anything today in the “quarterly report”
Imagine if data WAS released today. Anavex would have STILL went down.
I’m holding for the flop, then deciding if the hand is good or time to fold.
Daily pps I could care less. Trial results is what I care about.
No TLR PR as expected, yet down AVXL goes anyways. Seems like shorts were LOOKING for something to bring it down and Fiscal update sounded like a good reason……
Tomorrow, we rise
If not tomorrow, it WILL be less than 96 hours later
Good luck to all longs and those that believe CNS diseases might possibly have a new therapy.
The week has finally arrived.
That is what Missling did with the p2a trial. Analyze what subgroup worked best and geared the p2b around those findings.
Most are in a rush to start a p3, while Anavex seemed to take its time to try and get it right. Enroll the type of participants they wanted vs anyone.
We shall find out how they did in a week, probably less.
Missling effect, nah… it’s more like the BP plaque effect.
Everyone is so conditioned to see Alzheimer’s trials fail that they automatically assume it’ll be just another failure. You and I know what happens when you assume though. You end up making an A$$ out of yourself.
Let’s see if Missling can release trial results and make one out of all the experts, next day QBs and so on.
Happy Thanksgiving All.
You’d think they’d rather keep the original endpoint cause it’s an easier endpoint to hit than the updated one.
Then again……Adam didn’t mention that AT ALL.
More importantly, HAS there been an endpoint that Anavex didn’t hit since 2015 trials/results.
So far 100% on endpoints….right?
Looks like Monday is out for TLR PR
Oh no….. what do I do wise one.
Everyone will soon know who AVXL is!
There. Fixed it for you
Simple. Signal is strong enough, no doubt it’ll be approved.
Then the real question is what indications that Anavex is targeting will it NOT help.
Just a few more days of trying to convince people to get rid of their shares.
Right…? Because that other competitor EVERYONE wants in only to wait a year or two for TLR
Curious who’s the experts of interpreting the data? AF?
Typical shiny object syndrome.
Best part about it all…..
You do get a needle, but that’s to see if the correct amount of the drug is in your blood, NOT to administer said drug.
“We think differently”
Anavex website. I’m in and getting:
Expected Live Webcast
The live webcast has not started yet. Please check back in 6 minutes.
Roche released only the main outcome of the trial on Monday, planning to present detailed data at the Clinical Trials on Alzheimer's Disease conference in San Francisco on Nov. 30.
So just to be fair. Positive OR negative, Anavex will be presenting their results.
And the bar for the next Alzheimer’s approval will be raised.
No more throwing mud against the wall and hoping it sticks.
Man….I can’t WAIT to see if Blarcamesine is better than 6 cups of coffee.
Let’s see how that quote ages in less than 2 1/2 weeks
How out of the box it would be for Missling one day to announce
“ We have partnered with Amazon as our worldwide distributor of Blarcamesine.”
I understood that.
It changed recently as Missling was slated for that Conference as well.
I’d like to think what Missling believes Anavex is worth and what any OTHER Biotech thinks are Billions of dollars apart.
So, any takeover would be hostile. To think Anavex has defenses against one?
In a realistic scenario, the hostile co would still profit in the long run.
Looks like Missling will no longer be the speaker for the conference late November.
Daniel Klamer
Implementing Genetic Analysis in Clinical Trials to Illuminate Genetic Biomarkers in Rett Syndrome
Time: 1:45 pm
Day: Day Two
Details:
Implementing and executing clinical trial protocol for genetic analysis
Exploring whole blood transcriptomics analysis
Analysis of clinical endpoints and biomarkers of response
https://neurodevelopmental-drug-development.com/speaker/chrisopher-u-missling/
I think everyone underestimates the power of greed.
If the results are stellar, Anavex might as well have a partner lined up as well.
I want some of THAT kool-aid